Clinical trial
Study of TPI 287 in Patients With Advanced Malignancies
NCT00113724 · Cortice Biosciences, Inc., Industry · Completed
Key facts
| NCT number | NCT00113724 |
|---|---|
| Title | Study of TPI 287 in Patients With Advanced Malignancies |
| Official title | A Phase I, Open-Label, Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies |
| Lead sponsor | Cortice Biosciences, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Non-Hodgkin Lymphoma, Hodgkin Disease |
| Intervention type | Drug |
| Interventions | TPI 287 Injection |
| Enrollment | 48 |
| Start date | May 1, 2005 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Jun 10, 2005 |
| Last update posted | Jun 4, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: